UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
June 10, 2020
___________________________________
Phreesia, Inc.
(Exact name of registrant as specified in its charter)
___________________________________
Delaware
(State or other jurisdiction of incorporation or organization)
001-38977
(Commission File Number)
20-2275479
(I.R.S. Employer Identification Number)
432 Park Avenue South, 12th Floor
New York, New York 10016
(Address of principal executive offices and zip code)

(888) 654-7473
(Registrant's telephone number, including area code)
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per sharePHRThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 1.01. Entry into a Material Definitive Agreement.

On June 10, 2020, Phreesia, Inc. (the “Company”) entered into the First Amendment to the Strategic Alliance Agreement (the “Amendment”), effective as of July 1, 2020, with Allscripts Healthcare, LLC (“Allscripts”), to amend the Strategic Alliance Agreement by and between the Company and Allscripts, effective as of December 10, 2015 (the “Original Agreement” and as amended by the Amendment, the “Amended Agreement”).

Pursuant to the Amendment, the parties have agreed to amend certain pricing and fee terms and invoicing procedures, among other things. Additionally, pursuant to the Amended Agreement, the initial term has been extended until June 30, 2025 and shall automatically renew for successive one-year terms after such date, unless earlier terminated. Either party may terminate the Amended Agreement for convenience upon one year’s prior written notice, or immediately upon written notice if the Company is determined ineligible to participate in federal healthcare programs or upon certain change of control transactions. Additionally, either party may terminate the Amended Agreement upon an uncured material breach by the other party or upon the other party’s insolvency.

The foregoing summary of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amendment, a copy of which will be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ending July 31, 2020.





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 10, 2020Phreesia, Inc.
By:/s/ Thomas Altier
Name:Thomas Altier
Title:Chief Financial Officer